Miraculins Announces Publication of Peer-Reviewed Study That Demonstrates Scout DS(R) Is a Viable Alternative to Current Pre-Diabetes and Type 2 Diabetes Screening Methods

July 24, 2014

Miraculins Inc. CA:MOM -9.68% ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces the publication of results from the ENGINE (Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes) study, which highlights the effectiveness of the Company's Scout DS(R) NonInvasive Diabetes Screening Device. The study, which is available online ahead of press publication by the Journal of Clinical and Translational Endocrinology, concluded that the elimination of overnight fasting, the absence of blood, and the rapid, real-time communication of screening results are aspects of noninvasive skin fluorescence spectroscopy (Scout DS(R) measurement) that facilitate opportunistic screening of individuals at risk for type 2 diabetes, while delivering performance that is comparable to fasting plasma glucose and HbA1c testing for detection of abnormal glucose tolerance. The published article is entitled "Noninvasive Skin Fluorescence Spectroscopy for Detection of Abnormal Glucose Tolerance".

for the rest of the story, go to:  http://www.marketwatch.com/story/miraculins-announces-publication-of-peer-reviewed-study-that-demonstrates-scout-dsr-is-a-viable-alternative-to-current-pre-diabetes-and-type-2-diabetes-screening-methods-2014-07-24

Share This Story

Back